The search textbox has an autosuggest feature. When you enter three or more characters, a list of up to 10 suggestions will popup under the textbox. Use the arrow keys to move through the suggestions. To select a suggestion, hit the enter key. Using the escape key closes the listbox and puts you back at the textbox. The radio buttons allow you to toggle between having all search items start with or contain the text you entered in the search box.
A recombinant bispecific monoclonal antibody directed against both CD3 and epithelial cell adhesion molecule (EpCAM) with potential immunomodulating and antineoplastic activities. Solitomab attaches to both CD3-expressing T lymphocytes and EpCAM-expressing tumor cells, thereby selectively cross-linking tumor and T lymphocytes; this may result in the recruitment of cytotoxic T lymphocytes (CTL) to T lymphocyte/tumor cell aggregates and the CTL-mediated death of EpCAM-expressing tumor cells. CD3 is an antigen expressed on mature T cells; EpCAM, a cell surface protein, is expressed by a variety of tumor cells and is frequently found in head and neck cancers. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
|Synonym:||anti-EpCAM/anti-CD3 recombinant bispecific monoclonal antibody MT110|